These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11270370)

  • 1. Quinolone resistance-determining regions of gyrA and parC in Pasteurella multocida strains with different levels of nalidixic acid resistance.
    Cárdenas M; Barbé J; Llagostera M; Miró E; Navarro F; Mirelis B; Prats G; Badiola I
    Antimicrob Agents Chemother; 2001 Mar; 45(3):990-1. PubMed ID: 11270370
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
    J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom.
    Piddock LJ; Ricci V; McLaren I; Griggs DJ
    J Antimicrob Chemother; 1998 Jun; 41(6):635-41. PubMed ID: 9687102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.
    Deguchi T; Fukuoka A; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Ban Y; Kawada Y
    Antimicrob Agents Chemother; 1997 Mar; 41(3):699-701. PubMed ID: 9056017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium.
    Ruiz J; Castro D; Goñi P; Santamaria JA; Borrego JJ; Vila J
    J Med Microbiol; 1997 Jul; 46(7):623-8. PubMed ID: 9236748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
    Li Z; Deguchi T; Yasuda M; Kawamura T; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3293-5. PubMed ID: 9835531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Ezaki T; Saito I; Kawada Y
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1020-3. PubMed ID: 8849219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Maeda SI; Saito I; Kawada Y
    J Antimicrob Chemother; 1998 Mar; 41(3):418-20. PubMed ID: 9578173
    [No Abstract]   [Full Text] [Related]  

  • 11. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J; Perichon B; Duval J; Courvalin P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.
    Valdezate S; Vindel A; Echeita A; Baquero F; Cantó R
    Antimicrob Agents Chemother; 2002 Mar; 46(3):665-71. PubMed ID: 11850246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
    Mouneimné H; Robert J; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC.
    Gibreel A; Sjögren E; Kaijser B; Wretlind B; Sköld O
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3276-8. PubMed ID: 9835526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of gyrA mutations associated with fluoroquinolone resistance in Campylobacter coli by DNA sequence analysis and MAMA PCR.
    Zirnstein G; Helsel L; Li Y; Swaminathan B; Besser J
    FEMS Microbiol Lett; 2000 Sep; 190(1):1-7. PubMed ID: 10981681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
    Kanematsu E; Deguchi T; Yasuda M; Kawamura T; Nishino Y; Kawada Y
    Antimicrob Agents Chemother; 1998 Feb; 42(2):433-5. PubMed ID: 9527801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R; De La Campa AG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type II topoisomerase quinolone resistance-determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance.
    Goñi-Urriza M; Arpin C; Capdepuy M; Dubois V; Caumette P; Quentin C
    Antimicrob Agents Chemother; 2002 Feb; 46(2):350-9. PubMed ID: 11796341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.
    Oram M; Fisher LM
    Antimicrob Agents Chemother; 1991 Feb; 35(2):387-9. PubMed ID: 1850972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.